Greg Roumeliotis – VJRegenMed

The changing landscape of hospital-based cell and gene therapy manufacturing

Simon Ng — Thu, 27 Jan 2022 18:00:58 +0000

Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, discusses the evolving space of hospital-based cell and gene therapy (CGT) manufacturing. Cell and gene therapies are being developed very quickly to meet the growing demand in healthcare and there are ongoing efforts to make these therapies more accessible and affordable for patients. Mr Roumeliotis talks on the breadth of the CGT space, as well as promising non-viral vector and allogeneic cell therapies. He additionally highlights the role of Orgenesis in accelerating the manufacturing process of cell and gene therapies, increasing the availability of know-how and technology to stakeholders. This interview took place at Advanced Therapies Week 2022.

Challenges in decentralized manufacturing systems

Simon Ng — Thu, 27 Jan 2022 17:03:34 +0000

Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, provides an overview of major issues currently facing decentralized manufacturing, such as developing collaborative environments to foster innovation, as well as manufacturing accessible and affordable therapies of clinical quality. He additionally describes how Orgenesis Mobile Production Units and Labs (OMPULs) have enabled the point-of-care development of cell and gene therapies on a large-scale and the production of advanced therapies close to treatment centers and hospitals in various countries around the world. This interview took place at Advanced Therapies Week 2022.

Automating manufacturing with OMPULs

Simon Ng — Thu, 27 Jan 2022 17:03:33 +0000

Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, comments on the importance of automation in point-of-care manufacturing. Collaboration with startups, manufacturers and Orgenesis Mobile Production Units and Labs (OMPULs) has accelerated the point-of-care production and commercialization of advanced therapies. OMPULs operate in a decentralized system with partially centralized aspects, allowing efficient delivery of products. He additionally highlights the need for good manufacturing practice (GMP) readiness, as well as training programs developed by Orgenesis to further advance the cell and gene therapy industry. This interview took place at Advanced Therapies Week 2022.